Novo Nordisk A/S : A good level to buy
Entry price | Target | Stop-loss | Potential |
---|
DKK 419.7 |
DKK 453 |
DKK 399 |
+7.93% |
---|
The medium term support area around 400.4 DKK should allow Novo Nordisk A/S shares to re-establish an upward trend in the short term.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
Strengths● The share is getting closer to its long-term support in weekly data, at DKK 406.45, which offers good timing for buyers.
● Share prices are approaching a strong support area in daily data, which offers good timing for investors.
● Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
● Thanks to a sound financial situation, the firm has significant leeway for investment.
● Considering the small differences between the analysts' various estimates, the group's business visibility is good.
● The tendency within the weekly time frame is positive above the technical support level at 406.45 DKK
Weaknesses● Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
● Based on current prices, the company has particularly high valuation levels.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.
Surperformance is Buy on NOVO NORDISK A/S since 13/09/2023
.